SGMT Sagimet Biosciences Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1400118 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY7.5%
TTM EPS YoY33.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-29.5%
ROA-26.0%
ROIC (approx.)-43.4%
Asset turnover—
Leverage & solvency
Liabilities / assets14.1%
Debt / equity0.00x
Current ratio6.34x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.82x
Accruals ratio-4.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | — | — | $2.00M | — |
| R&D expense | $39.05M | $38.44M | $19.78M | $24.92M |
| SG&A expense | $17.84M | $16.01M | $12.96M | $6.14M |
| Operating income | -$56.89M | -$54.45M | -$30.74M | -$31.05M |
| Income tax | $0 | $0 | — | — |
| Net income | -$51.04M | -$45.57M | -$27.88M | -$30.50M |
| EPS (basic) | -1.58 | -1.45 | -2.66 | -165.20 |
| EPS (diluted) | -1.58 | -1.45 | -2.66 | -165.20 |
| Weighted avg. shares (diluted) | 32.35M | 31.35M | 10.46M | 184,619 |
| Balance sheet | ||||
| Cash & equivalents | $35.02M | $75.84M | $75.14M | $158,000 |
| Short-term investments | $78.10M | $75.41M | $19.76M | $32.19M |
| Current assets | $116.40M | $152.77M | $96.65M | $32.79M |
| Total assets | $116.48M | $160.26M | $96.72M | $33.03M |
| Current liabilities | $5.10M | $4.45M | $5.65M | $5.28M |
| Total liabilities | $5.10M | $4.45M | $5.65M | $5.36M |
| Shareholders' equity | $111.38M | $155.81M | $91.06M | -$186.95M |
| Shares outstanding | — | — | 0 | 185,084 |
| Cash flow statement | ||||
| Operating cash flow | -$45.65M | -$42.44M | -$23.77M | -$24.49M |
| Investing cash flow | $4.56M | -$61.68M | $12.58M | -$32.01M |
| Financing cash flow | $275,000 | $104.82M | $86.17M | -$73,000 |
| Stock-based compensation | $6.45M | $5.29M | $4.99M | $1.88M |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.